Advertisement
Advertisement
U.S. markets closed
S&P Futures
4,133.50 -13.25 (-0.32%) Dow Futures
32,678.00 -79.00 (-0.24%) Nasdaq Futures
13,179.00 -49.75 (-0.38%) Russell 2000 Futures
1,915.00 -6.80 (-0.35%) Crude Oil
87.95 -1.06 (-1.19%) Gold
1,790.40 -0.80 (-0.04%)
Nevro Corp. (NVRO)
NYSE - Nasdaq Real Time Price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
Advertisement
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Performance Outlook
| Previous Close | 45.46 |
| Open | 44.54 |
| Bid | 43.15 x 800 |
| Ask | 51.33 x 1000 |
| Day's Range | 43.95 - 47.95 |
| 52 Week Range | 39.41 - 127.97 |
| Volume | |
| Avg. Volume | 530,582 |
| Market Cap | 1.667B |
| Beta (5Y Monthly) | 0.96 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.90 |
| Earnings Date | Nov 07, 2022 - Nov 11, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 66.33 |
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Subscribe to Yahoo Finance Plus to view Fair Value for NVRO
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
- Nevro Corp.Analyst Report: LivaNova PLCU.K.-based LivaNova was born of a combination between Cyberonics in the U.S. and Sorin in Italy. The medical device firm is primarily focused on cardiovascular and cardiopulmonary solutions (with surgical heart valves, heart-lung machines, and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management segment. LivaNova derives roughly half of its revenue from the U.S. market, another 21% from Europe, and the remainder from the rest of the world.RatingFair ValueEconomic Moat3 days agoMorningstar
- Zacks
Nevro (NVRO) Q2 Earnings Beat Estimates, FY22 View Revised
Nevro's (NVRO) worldwide revenues improve on a year-over-year basis in Q2, partly owing to robust domestic performance.
- Zacks
Nevro (NVRO) Reports Q2 Loss, Misses Revenue Estimates
Nevro (NVRO) delivered earnings and revenue surprises of 12.35% and 0.43%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
- PR Newswire
Nevro Reports Second Quarter 2022 Financial Results, Provides Third Quarter 2022 Guidance and Updates Full-Year 2022 Guidance
Nevro Corp. (NYSE: NVRO), delivering comprehensive, life-changing solutions for the treatment of chronic pain, today reported its financial results for the second quarter ended June 30, 2022, provided guidance for the third quarter of 2022 and updated its full-year 2022 guidance.
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
© 2022 Yahoo. All rights reserved.
